Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone

Long-Time Partners Decide Fate Of Two Drugs

Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.

Illustration of abstract neuron on a blue background
Ionis will bolster its in-house neurology portfolio with wholly-owned ION582 • Source: Shutterstock

Long-time collaborators Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced updates for two programs in mid-stage clinical development on 16 May, reporting that they will end development of BIIB105 after the drug failed in a Phase I/II clinical trial in amyotrophic lateral sclerosis (ALS). Ionis also revealed updated results from a Phase I/IIa trial of ION582 (BIIB121) in Angelman syndrome and said it will take the drug into Phase III on its own after Biogen opted out of the program.

Key Takeaways

  • Biogen and Ionis will discontinue development of BIIB105 for ALS after the drug failed to provide clinical benefit in a Phase I/II study.

Both companies traded lower on the updates, with Biogen closing down 2.2% at $230.04 per share and Ionis ending the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D